Contributions
Abstract: P1130
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Neurofilament light (NFL) is a biomarker of axonal damage and is the best studied biochemical biomarker of disease activity and treatment response in patients with relapsing remitting multiple sclerosis (RRMS). Development of the bioassay made it possible to determine NFL levels in healthy controls. However, until recently, NFL has only been determined in cerebrospinal fluid (CSF). This has limited the usefulness of NFL as a biomarker in clinical care of MS.
Objective: Determine the correlation between serum and CSF NFL levels and investigate the response from natalizumab treatment on serum NFL levels.
Methods: 74 pairs of serum and CSF samples were obtained simultaneously from patients with relapsing forms of MS. They were collected from 31 patients in a prospective manner prior to and once again after 6 or 12 months of natalizumab treatment. In 12 patients, samples were only obtained prior to treatment and not at follow up.
CSF NFL levels were determined using the UmanDiagnostics NF-light enzyme-linked immunoassay (ELISA), previously described.Serum NFL levels were determined using the NF-Light kit from UmanDiagnostics transferred onto the Simoa platform using a homebrew kit (Quanterix Corp, Boston, MA, USA), as previously described (Gisslén M et al., EBioMedicine. 2015 Nov 22;3:135 -40).
Results: The correlation between serum and CSF NFL was r=0.977 (p< 0.001). Natalizumab treatment during 6 or 12 months reduced mean CSF levels from 2442 ng/L (range 230 - 27 310) to 481 ng/L (200-1 510), p< 0.001). The corresponding reduction in serum was 35 pg/mL (range 8 - 394) to 13 pg/mL (range 4 - 33), p< 0.001.
Conclusion: Serum NFL has high potential to become a new biomarker in RRMS for monitoring disease activity and the effects on axonal damage from disease modifying treatments.
Disclosure: Lenka Novakova, Henrik Zetterberg, and Kaj Blennow have no discloures.
Clas Malmeström has received honoraria for lectures and advisory boards from and Novartis
Markus Axelsson have had compensation for lectures and/or advisory boards from Biogen, Genzyme and Novartis.
Jan Lycke has received travel support and/or lecture honoraria from Biogen, Novartis, Teva and Genzyme/SanofiAventis; has served on scientific advisory boards for Almirall, Teva, Biogen, Novartis and Genzyme/SanofiAventis; serves on the editorial board of the Acta Neurologica Scandinavica; has received unconditional research grants from Biogen, Novartis and Teva.
Abstract: P1130
Type: Poster
Abstract Category: Pathology and pathogenesis of MS - Biomarkers
Background: Neurofilament light (NFL) is a biomarker of axonal damage and is the best studied biochemical biomarker of disease activity and treatment response in patients with relapsing remitting multiple sclerosis (RRMS). Development of the bioassay made it possible to determine NFL levels in healthy controls. However, until recently, NFL has only been determined in cerebrospinal fluid (CSF). This has limited the usefulness of NFL as a biomarker in clinical care of MS.
Objective: Determine the correlation between serum and CSF NFL levels and investigate the response from natalizumab treatment on serum NFL levels.
Methods: 74 pairs of serum and CSF samples were obtained simultaneously from patients with relapsing forms of MS. They were collected from 31 patients in a prospective manner prior to and once again after 6 or 12 months of natalizumab treatment. In 12 patients, samples were only obtained prior to treatment and not at follow up.
CSF NFL levels were determined using the UmanDiagnostics NF-light enzyme-linked immunoassay (ELISA), previously described.Serum NFL levels were determined using the NF-Light kit from UmanDiagnostics transferred onto the Simoa platform using a homebrew kit (Quanterix Corp, Boston, MA, USA), as previously described (Gisslén M et al., EBioMedicine. 2015 Nov 22;3:135 -40).
Results: The correlation between serum and CSF NFL was r=0.977 (p< 0.001). Natalizumab treatment during 6 or 12 months reduced mean CSF levels from 2442 ng/L (range 230 - 27 310) to 481 ng/L (200-1 510), p< 0.001). The corresponding reduction in serum was 35 pg/mL (range 8 - 394) to 13 pg/mL (range 4 - 33), p< 0.001.
Conclusion: Serum NFL has high potential to become a new biomarker in RRMS for monitoring disease activity and the effects on axonal damage from disease modifying treatments.
Disclosure: Lenka Novakova, Henrik Zetterberg, and Kaj Blennow have no discloures.
Clas Malmeström has received honoraria for lectures and advisory boards from and Novartis
Markus Axelsson have had compensation for lectures and/or advisory boards from Biogen, Genzyme and Novartis.
Jan Lycke has received travel support and/or lecture honoraria from Biogen, Novartis, Teva and Genzyme/SanofiAventis; has served on scientific advisory boards for Almirall, Teva, Biogen, Novartis and Genzyme/SanofiAventis; serves on the editorial board of the Acta Neurologica Scandinavica; has received unconditional research grants from Biogen, Novartis and Teva.